Related Experiment Video
Updated: Apr 18, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Targeting HER2 for the treatment of breast cancer
Mothaffar F Rimawi1, Rachel Schiff, C Kent Osborne
1Lester and Sue Smith Breast Center and the Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas, 77030; email: rimawi@bcm.edu , rschiff@bcm.edu , kosborne@bcm.edu.
Abstract:
HER2 (ErbB2), a member of the HER family of tyrosine kinase receptors (HER1-4), is a major driver of tumor growth in 20% of breast cancers. Treatment with the anti-HER2 monoclonal antibody trastuzumab has revolutionized the outcome of patients with this aggressive breast cancer subtype, but intrinsic and acquired resistance is common. Growing understanding of the biology and complexity of the HER2 signaling network and of potential resistance mechanisms has guided the development of new HER2-targeted agents. Combinations of these drugs to more completely inhibit the HER receptor layer, or combining HER2-targeted agents with agents that target downstream signaling, alternative pathways, or components of the host immune system, are being vigorously investigated in the preclinical and clinical settings. As a result, the list of more effective and well tolerated FDA-approved new regimens for patients with HER2+ tumors is constantly growing.
Insights
HER2-positive breast cancer treatment has advanced with trastuzumab, but resistance is common. New combination therapies targeting HER2 signaling and resistance mechanisms offer improved outcomes for patients.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Human Epidermal growth factor Receptor 2 (HER2) drives tumor growth in 20% of breast cancers.
- Trastuzumab, an anti-HER2 antibody, transformed treatment but faces resistance.
- Understanding HER2 signaling and resistance is key to developing new therapies.
Purpose of the Study:
- To review the evolving landscape of HER2-targeted therapies for breast cancer.
- To highlight the development of novel agents and combination strategies.
- To discuss strategies for overcoming intrinsic and acquired resistance to HER2-targeted treatments.
Main Methods:
- Review of preclinical and clinical investigations.
- Analysis of emerging HER2-targeted agents and drug combinations.
- Examination of resistance mechanisms and therapeutic strategies.
Main Results:
- Development of new HER2-targeted agents beyond trastuzumab.
- Investigation of combination therapies targeting HER2, downstream pathways, and the immune system.
- Growing list of FDA-approved regimens for HER2-positive tumors.
Conclusions:
- HER2-targeted therapy has significantly improved outcomes for HER2-positive breast cancer.
- Overcoming resistance through novel drug combinations is a critical area of research.
- Continued research promises more effective and tolerable treatment options for patients.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:38Mitogens and the Cell Cycle
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers